 |
2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate |
|---|---|
| Trade Name | |
| Orphan Indication | Primary biliary cirrhosis |
| USA Market Approval | USA |
| USA Designation Date | 2016-11-07 00:00:00 |
| Sponsor | CymaBay Therapeutics;7999 Gateway Boulevard, Suite 130;Newark, California, 94560 |
